Figure 3.

HIV-1 RNA viral load over 192 weeks within HIV-1 patients receiving DTG monotherapy (n = 68) or cART (n = 33)^a. Patients had the option to switch from current therapy (n = 18) to dolutegravir monotherapy, irrespective of the primary outcome (viral failure), which some patients did after week 96 or later. *One patient in the dolutegravir monotherapy group showed viral failure on dolutegravir monotherapy but was excluded from the study due to a major protocol violation. **This patient on combination anti-retroviral therapy showed a single HIV-1 plasma RNA of 586 copies/mL, which, although above the defined level of a blip, did not constitute viral failure. During the next study visit, which occurred after week 192, an undetectable viral load on the same therapy was measured. ^aData up to week 48 previously reported as part of the EARLY-SIMPLFIED interim analysis [12]. Abbreviations: DTG, dolutegravir; HIV-1, human immunodeficiency virus type 1.